Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali

@inproceedings{Dama2017ReducedEV,
  title={Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali},
  author={Souleymane Dama and Hamidou Niangaly and A. D. Ouattara and Issaka Sagara and Sekou Sissoko and Oumar Bila Traore and Amadou Bamadio and Niawanlou Dara and Moussa Djimd{\'e} and Mohamed Lamine Alhousseini and Siaka Goita and Hamma Maiga and Antoine Dara and Ogobara K. Doumbo and Abdoulaye A. Djimd{\'e}},
  booktitle={Malaria Journal},
  year={2017}
}
Artemisinin-based combination therapy is the recommended first-line treatment for uncomplicated falciparum malaria worldwide. However, recent studies conducted in Mali showed an increased frequency of recurrent parasitaemia following artemether–lumefantrine (AL) treatment. Study samples were collected during a large WANECAM study. Ex-vivo Plasmodium falciparum sensitivity to artemether and lumefantrine was assessed using the tritiated hypoxanthine-based assay. The prevalence of molecular… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS